TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Once Weekly GLP-1 in Persons With Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, age 18 to 69;~2. Chronic (e.g., duration of injury greater than 3 years) stable SCI (regardless of level of neurological injury);~3. ASIA A-D (non-ambulatory defined as not able to weight bear for more than 20% of the day);~4. Obese Percent Body Fat defined as \> 25% for men and \> 35% for women (as determined by screening DXA scan);~5. Insulin Resistant as determined at screening: (FPI, ≥15 µU/ml); -OR-~6. Pre-diabetic, as determined by any one of the following:~   1. HbA1C ≥ 5.7% and \< 6.4%; or~  2. Impaired glucose tolerance by FSG ≥100 mg/dl and \< 125 mg/dl and/or the 2 hour serum glucose concentration (after an OGTT) ≥ 140 mg/dl and \< 200 mg/dl~Exclusion Criteria:~1. Personal history of or family history of medullary thyroid carcinoma;~2. History of multiple endocrine neoplasia syndrome type 2;~3. History of pancreatitis;~4. Existing diagnosis of diabetes mellitus, or the results from screening OGTT that identify diabetes mellitus (previously undiagnosed); laboratory thresholds for exclusion will be as follows: HbA1C ≥6.5%, fasting plasma glucose \>126 mg/dl, or 2 hour value \>200 mg/dl;~5. Receiving treatment for impaired glucose metabolism (i.e., insulin, secretagogues, or other agents to modify peripheral insulin sensitivity or serum glucose concentration);~6. Reduced kidney function (by glomerular filtration rate (GFR \<60 ml/min) or liver function tests (any single LFT ≥ 2.5 times above the upper limit of normal) as determined by test results at screening and any time point of the study;~7. Elevated calcitonin level (as determined at screening to rule out thyroid cancer);~8. Pregnancy or women who may become pregnant during the course of the study, or those who are nursing;~9. Medically unstable;~10. Acute illness or infection;~11. Diminished mental capacity; and~12. Inability or unwillingness of subject to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Semaglutide 1MG Injection [Ozempic] (Type: EXPERIMENTAL): 20 subjects will be randomized to receive once weekly injection of Semaglutide (Ozempic1mg) for 26 weeks.
- No Intervention (Type: OTHER): 10 subjects will be randomized to receive no intervention for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Inflammatory Response Secondary Using Intravenous Anesthesia Versus Inhalation Anesthesia With Halogenated Agents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* candidates to Lung resection surgery at Hospital General Universitario Gregorio Marañón (males and females)~* willing to participate and sign informed consent~* age \> 18 años and legal capable~* no urgent surgery.~* FEV1 \>50% or CVF \> 50%~* no previous steroids or immunosuppressors chronic treatment (three months before the surgery)~Exclusion Criteria:~* pregnancy and breast feeding~* propofol or sevoflurane hypersensibility.~* have received blood derivate product within 10 days before surgery.~* when protective pulmonary ventilation is not possible during one Lung ventilation.~* Heart failure \> II NYHA within one week before surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- propofol (Type: ACTIVE_COMPARATOR): propofol doses to maintain hypnoses between 40-60 bis(Bispectral Index Scale)during the lung resection surgery
- sevoflurane (Type: EXPERIMENTAL): Sevoflurane doses to maintain hypnoses between 40-60 bis(Bispectral Index Scale)during the lung resection surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~HCV Positive With HCV RNA\>100,000 iu/ml Genotype 1; COHORT A- non responders or partial~Exclusion Criteria:~HIV HBV co-infection Decompensated liver disease Liver disease due to causes other than HCV, AFP\>200ng/ml

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort B (Type: EXPERIMENTAL): None
- Cohort A (Type: EXPERIMENTAL): Dose study drug in subjects who have previously failed to respond to interferon based therapies

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-23 year old college females who are planning to return to the university for the next fall semester.~Exclusion Criteria:~* Pregnancy or planned pregnancy.~* Prior receipt of HPV vaccine.~* Greater than four lifetime sexual partners.~* Immunosuppression.~* Anti-coagulant therapy.~* Breastfeeding.~* History of abnormal pap smear.~* Allergy to vaccine components.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 23 Years
- Healthy Volunteers: t

Study Arms:
- 6 mon. 3rd dose of quadrivalent human papillomavirus vaccine (Type: ACTIVE_COMPARATOR): Receipt of three doses of quadrivalent human papillomavirus vaccine according to the regular schedule of 0,2, and 6 months.
- 12 mon. 3rd dose of quadrivalent human papillomavirus vaccine (Type: ACTIVE_COMPARATOR): Receipt of three doses of quadrivalent human papillomavirus vaccine on a delayed schedule of 0,2, and 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Project MADD - NIH Underage DUI and Ride

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Parent and teen both consent (forming a dyad testing unit); They are part of GfK's KnowledgePanel pool of participants~Exclusion Criteria:~* Outside of the teen age range

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- MADD Materials (Type: EXPERIMENTAL): Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
- Surgeon General Materials (Type: EXPERIMENTAL): Information published by the Surgeon General about teens and drinking
- Control (Type: NO_INTERVENTION): TAU

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anastrozole in Patients With Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previous documentation of mean pulmonary artery pressure \> 25 mm Hg with a pulmonary capillary wedge pressure (or left ventricular end-diastolic pressure) \< 16 mm Hg and PVR \> 3 WU at any time before study entry.~* Diagnosis of PAH which is idiopathic, heritable, drug- or toxin-induced, or associated with connective tissue disease, congenital heart disease, portal hypertension, or HIV infection.~* Most recent pulmonary function tests with FEV1/FVC \>50% AND either a) total lung capacity \> 70% predicted or b) total lung capacity between 60% and 70% predicted with no more than mild interstitial lung disease on computerized tomography scan of the chest~* Ability to perform six minute walk testing without limitations in musculoskeletal function or coordination.~* If female, post-menopausal state, defined as:~* \> 50 years old AND~* a) have not menstruated during the preceding 12 months OR~* b) have follicle-stimulating hormone (FSH) levels (\> 40 IU/L) OR~* \< 50 years and FSH (\> 40 IU/L) OR~* having had a bilateral oophorectomy~* Informed consent~Exclusion Criteria:~* Treatment with estrogen or anti-hormone therapy (tamoxifen, fulvestrant, etc.)~* WHO Class IV functional status~* History of breast cancer~* Clinically significant untreated sleep apnea~* Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection fraction \< 45% on echocardiography~* Initiation of PAH therapy (prostacyclin analogues, endothelin-1 receptor antagonists, phosphodiesterase-5 inhibitors) within three months of enrollment; the dose must be stable for at least 3 months prior to Baseline Visit~* Hormone therapy~* Hospitalized or acutely ill~* Renal failure (creatinine \> 2.0)~* Child-Pugh Class C cirrhosis~* Current or recent (\< 6 months) chronic heavy alcohol consumption~* Current use of another investigational drug (non-FDA approved) for PAH~* Enrollment in a clinical trial within one month of screening~* Age \< 18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anastrozole (Type: EXPERIMENTAL): 1 mg tablet by mouth once daily for 3 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet by mouth once daily for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Superiority of ArTiMist Versus Quinine in Children With Severe Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient's legally acceptable representative has provided informed consent and the patient has assented (where relevant) to participation in the trial~2. The patient is a child that weighs between 5.00 kg and 15.00 kg inclusive~3. The patient has falciparum malaria as evidenced by thick or thin blood smears of ≥ 500 P Falciparum per mcl (patients with mixed infections may be included provided ≥ 500 P Falciparum per mcl)~4. The patient has either:~   * severe or complicated falciparum malaria as determined by the investigator based on the WHO criteria for severity, and/or~  * uncomplicated falciparum malaria but is unable to tolerate oral medication as a result of gastrointestinal complications such as vomiting or diarrhoea.~Exclusion Criteria:~1. The patient's legally acceptable representative does not provide informed consent for participation, or the child if capable, does not assent to participation in the trial.~2. Ability to tolerate oral therapy~3. Patient has received any antimalarial therapy within the 7 days prior to first study drug administration.~4. Patient has evidence of significant co-infections (this does not include mixed Plasmodium infections).~5. Patient has a contraindication, allergy or is otherwise intolerant to either artemether or quinine .

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ArTiMist (Type: EXPERIMENTAL): None
- Quinine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IV Acetaminophen as an Adjunct Analgesic in Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* (1) subjects who clinically consented to elective sternotomy for coronary artery bypass grafting (CABG), heart valve repair or replacement under general anesthesia, and (2) ages between 18 and 75 years~Exclusion Criteria:~* (1) subject refusal, (2) non-English speaking, (3) previous chronic or neuropathic pain, (4) previous chronic use of opioids, (5) history of psychiatric disorder, (6) allergy to acetaminophen, (7) severely impaired liver and kidney function and (8) previous sternotomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IV acetaminophen (Type: EXPERIMENTAL): Study subjects receiving IV acetaminophen
- Normal saline (Type: PLACEBO_COMPARATOR): Study subjects receiving placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OPTI-FREE® PureMoist® for Presbyopic Contact Lens Wearers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must sign an informed consent document;~* Current adapted two-week/monthly replacement soft contact lens wearers (at least 2 months) with symptoms of contact lens induced dryness;~* Near spectacle add of +0.50 or greater;~* Best corrected visual acuity (BCVA) to 20/30 or better in each eye at distance;~* Willing to wear lenses for a minimum of 5 days per week, 6 hours per day, and attend all study visits;~* Currently using a non-Alcon multi-purpose solution to care for lenses (at least 2 months);~* Use of digital devices (eg, smart phone, tablet, laptop computer, or desktop computer) for 20 consecutive minutes at least twice a week and willing to continue the same pattern for the duration of the study;~* Other protocol-specific inclusion criteria may apply.~Exclusion Criteria:~* Extended wear contact lens wearer (sleeps in lenses 1 or more nights per week);~* Any anterior segment infection, inflammation, disease, or abnormality that contraindicates contact lens wear as determined by the investigator;~* Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator, including use of any topical ocular medications that would require instillation during contact lens wear;~* Monocular (only 1 eye with functional vision) or fit with only 1 lens;~* Known sensitivity to any ingredients in OFPM;~* Prior refractive surgery;~* History of herpetic keratitis, ocular surgery, or irregular cornea;~* Pathological dry eye that precludes contact lens wear;~* Use of mechanical eyelid therapy or eyelid scrubs within 14 days before Visit 1 and not willing to discontinue during the study;~* Participation in any clinical study within 30 days of Visit 1;~* Currently using or have not discontinued Restasis®, Xiidra® or a topical steroid within the past 7 days;~* Other protocol-specific exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- OFPM, then HMPS (Type: OTHER): OPTI-FREE® PureMoist® multi-purpose contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
- HMPS, then OFPM (Type: OTHER): Subject's habitual multi-purpose contact lens solution in Period1, followed by OPTI-FREE® PureMoist® contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be 18 to 90 years of age, inclusive,~* Female patients can participate if they are surgically sterilized or postmenopausal for at least 1 year or her sexual partner has had a vasectomy~* Female of childbearing potential has had normal menstrual periods for 3 months and negative serum pregnancy test and agree to practice highly effective methods of birth control during treatment and for at least 7 days after last dose~* Intraoperative/postoperative enrollment with visual confirmation (presence of pus within the abdominal cavity) of an intra-abdominal infection associated with peritonitis~* Confirmation of infection by surgical intervention within 24 hours of entry: evidence of systemic inflammatory indicators; physical findings consistent with intra-abdominal infection; supportive radiologic imaging findings of intra-abdominal infections~Exclusion Criteria:~* Patient is diagnosed with traumatic bowel perforation undergoing surgery within 12 hours; perforation of gastroduodenal ulcers undergoing surgery within 24 hours. Other intra-abdominal processes in which primary etiology is not likely to be infectious~* Patient has abdominal wall abscess or bowel obstruction without perforation or ischemic bowel without perforation~* Patients whose surgery will include staged abdominal repair, or open abdomen technique, or marsupialization~* Patient has suspected intra-abdominal infections due to fungus, parasites, virus or tuberculosis~* Patient is considered unlikely to survive the 6- to 8-week study period or has a rapidly progressive or terminal illness, including septic shock that is associated with a high risk of mortality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Ceftazidime-Avibactam plus metronidazole (Type: EXPERIMENTAL): None
- Meropenem (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-ranging Study in Patients With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant had given written informed consent to participate in the study in accordance with local regulations.~* Adult participants 18 years and older with a diagnosis of type 1 diabetes mellitus (T1D) made at least 1 year prior to informed consent.~* Participants were being treated with insulin or insulin analog delivered via continuous subcutaneous insulin infusion (CSII) or multiple daily injection (MDI).~* At the Screening Visit, A1C had to be between 7.0% and 10.0%.~* Females of childbearing potential had to use an adequate method of contraception and have a negative pregnancy test.~Exclusion Criteria:~* Use of antidiabetic agent other than insulin or insulin analog at the time of screening.~* Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to screening.~* Chronic systemic corticosteroid use.~* Type 2 diabetes mellitus (T2DM), or severely uncontrolled T1D as determined by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo-matching sotagliflozin tablets, once daily, orally for 12 weeks.
- Sotagliflozin 75 mg (Type: EXPERIMENTAL): Sotagliflozin 75 mg (one 75 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
- Sotagliflozin 200 mg (Type: EXPERIMENTAL): Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
- Sotagliflozin 400 mg (Type: EXPERIMENTAL): Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has stage 1-5 chronic kidney disease (CKD) as defined by the Kidney Disease Outcomes Quality Initiative (K/DOQI) with proteinuria, including any of the following aetiologies: immunoglobulin (IgA) nephropathy, polycystic kidney disease (PCKD), congenital abnormalities, reflux nephropathy, focal segmental glomerulosclerosis, minimal change nephropathy, and membranous nephropathy.~Exclusion Criteria:~* Required peritoneal dialysis or haemodialysis.~* Has kidney disease due to diabetes mellitus, vasculitis, systemic lupus erythematosus, or known renovascular disease; antiglomerular basement membrane disease; or is on immunosuppressive medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sitaxsentan (Type: EXPERIMENTAL): Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
- Nifedipine (Type: ACTIVE_COMPARATOR): Nifedipine 30 mg extended release tablets, orally administered once daily (open label arm)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for sitaxsentan, orally administered once daily (double blind arm)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete